ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO668

Clinical Features and Outcomes in Anti-Glomerular Basement Membrane Glomerulonephritis Patients with Onset of Noninfectious Fever

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Shi, Xiaoxiao, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, BEIJING, China
  • Xu, Lei, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, BEIJING, China
  • Yin, Huanhuan, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, BEIJING, China
  • Wen, Yu bing, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, BEIJING, China
  • Li, Xuemei, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, BEIJING, China
  • Chen, Limeng, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, BEIJING, China
Background

To summarize the clinical features and outcomes of anti-glomerular basement membrane (anti-GBM) glomerulonephritis (GN) with onset of non-infectious fever.

Methods

We retrospectively reviewed the clinical records and follow-up data of 58 patients with anti-GBM GN in our hospital from May 2010 to May 2019.

Results

Among the 58 anti-GBM GN patients, 39 patients (67.2%) presented with fever initially. After careful screening of serological and urinary tests, pathogenic cultures, and CT scans, 28 (48.3%) patients had no evidence of infections. These non-infectious febrile patients had a female/male ratio of 1.3:1, and the average age was 46±18 years old. Six (21.4%) patients were complicated with pulmonary hemorrhage. Compared to the non-febrile anti-GBM GN patients (n=19), they showed higher CRP levels (65.4 vs. 24.5 mg/L, P=0.045) and higher anti-GBM antibody titers (175±41 vs. 132±62 EU/ml, P=0.012). In kidney, they presented milder proteinuria (2.51±2.51 vs. 4.69±2.41 g/d, P=0.016), despite similar serum creatinine (906±414 vs. 995±604 μmol/L) and eGFR (4.66 vs. 4.40 mL/min/1.73m2) levels (P>0.05). Crescentic GN was diagnosed in 11 (84.6%) of 13 patients who had renal biopsy. At onset, 82.1% patients were treated by antibiotics which didn't work. All patients received immunosuppressive treatment later, and 26 of them had combined plasma exchange therapy. They received more plasma exchanges (7.2±3.9 vs. 4.0±3.5, P=0.006) and had a longer hospital stay (42±21 vs. 29±15 days, P=0.020) compared to the non-febrile group. During follow-up, the renal survival rate at 1, 3 and 5 year was 20.8%, 13.6% and 10.0%, which were similar with the non-febrile group (18.8%, 7.1%, 0%) (P>0.05). Among all the 58 anti-GBM GN patients, Kaplan-Meier survival analysis showed that oliguria, pulmonary hemorrhage, initial eGFR, and anti-GBM antibody titers were prognostic factors for renal outcome (P<0.05), but fever was not a predictor of it. Multivariate Cox regression analysis showed higher initial eGFR was an independent risk factor for ESRD (RR=0.80, 95%CI (0.69, 0.93), P=0.004).

Conclusion

Fever in anti-GBM GN may be part of systemic inflammations instead of infections. Anti-GBM GN patients with onset of non-infectious fever presented more severe systemic inflammations and needed more intensive treatment.